apl. Prof. Dr. Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis (2020) Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, et al. Conference contribution Dietary short-term fiber interventions in arthritis patients increase systemic scfa levels and regulate inflammation (2020) Dürholz K, Hofmann J, Iljazovic A, Häger J, Lucas S, Sarter K, Strowig T, et al. Journal article Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial (2020) Schett G, Bainbridge C, Berkowitz M, Davy K, Fernandes S, Griep E, Harrison S, et al. Journal article Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis (2020) Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, et al. Journal article TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL (2020) Stone JH, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Schenker H, Rech J, Tascilar K, Hagen M, Schoenau V, Sergeeva M, Selvakumar M, et al. Conference contribution PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA) (2020) Rech J, Tascilar K, Schenker H, Sergeeva M, Selvakumar M, Konerth L, Prade J, et al. Conference contribution LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Rech J, Tascilar K, Schenker H, Hagen M, Sergeeva M, Selvakumar M, Konerth L, et al. Conference contribution IMPACT OF METHOTREXATE ON DISEASE PATTERN IN ACTIVE PSORIATIC ARTHRITIS PATIENTS ELIGIBLE FOR A RANDOMIZED CLINICAL TRIAL WITH USTEKINUMAB: COMPARATIVE BASELINE DATA FROM MULTICENTRE INVESTIGATOR-INITIATED MUST TRIAL (2020) Rossmanith T, Koehm M, Kiltz U, Rech J, Burmester GR, Kellner H, Bulczak-Schadendorf A, et al. Conference contribution STRUCTURAL ENTHESEAL LESIONS IN PSORIASIS PATIENTS ARE ASSOCIATED WITH AN INCREASED RISK OF PROGRESSION TO PSORIATIC ARTHRITIS - A PROSPECTIVE COHORT STUDY (2020) Simon D, Tascilar K, Kleyer A, Bayat S, Kampylafka E, Hueber A, Rech J, et al. Conference contribution